LifeSci Capital initiated coverage of Adagene (ADAG) with an Outperform rating and $8 price target
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADAG:
- Adagene and Third Arc Bio Forge Licensing Agreement for Cancer Therapy Development
- Adagene announces licensing agreement with Third Arc Bio
- Adagene files to sell 10.625M ordinary shares or 8.5M ADSs for holders
- Adagene says first patient dosed in Phase 2 study of muzastotug, KEYTRUDA
- Tempest Therapeutics and Adagene’s Promising Advances in Liver Cancer Treatment